Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates

Abstract

A summary of the key technological advancements in the preparation of antibody–oligonucleotide conjugates (AOCs) and the distinct advantages and disadvantages of AOCs as novel therapeutics are presented. The merits and demerits of the different approaches to conjugating oligonucleotides to antibodies, antibody fragments or other proteins, mainly from the perspective of AOC purification and analytical characterizations, are assessed. The lessons learned from in vitro and in vivo studies, especially the findings related to silencing, trafficking, and cytotoxicity of the conjugates, are also summarized.

Keywords

• antibody-oligonucleotide conjugates (AOCs)
• oligonucleotide
• siRNA
• precision medicine